Site icon pharmaceutical daily

Global Gastrointestinal Partnering 2016-2023: Trends, Players and Financials of Over 480 Partnerships – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

Global Gastrointestinal Partnering 2016 to 2023 provides the full collection of gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering gastrointestinal deals.

The report presents financial deal terms values for gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gastrointestinal dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading gastrointestinal deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to gastrointestinal deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all gastrointestinal partnering deals by specific gastrointestinal target announced since 2016. The chapter is organized by specific gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all gastrointestinal partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in gastrointestinal partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2016 to 2023 includes:

The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2016 to 2023, available deals and contracts are listed by:

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 480 gastrointestinal deals.

A Selection of Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/tkn6hb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version